Tumour necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinoma
- 31 December 1994
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 30 (2), 162-167
- https://doi.org/10.1016/0959-8049(94)90079-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Heterogeneity of tumour necrosis factor production in renal cell carcinomaEuropean Journal Of Cancer, 1992
- Evidence for the involvement of interleukin 6 in experimental cancer cachexia.JCI Insight, 1992
- Interleukin-6 and renal cell cancer: Production, regulation, and growth effectsCancer Immunology, Immunotherapy, 1992
- Rapid acquisition of an enhanced capacity to produce tumor necrosis factor, alpha/beta interferon, and interleukin 6 after implantation of tumor cellsCytokine, 1991
- Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluidsThe Lancet, 1991
- Classic and Modern Prognostic Indicators in Renal Cell CarcinomaUrologia Internationalis, 1991
- Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomasFEBS Letters, 1989
- Tumor Necrosis Factor Not Detectable in Patients With Clinical Cancer CachexiaJNCI Journal of the National Cancer Institute, 1988
- Action of recombinant human interleukin 6, interleukin 1β and tumor necrosis factor α on the mRNA induction of acute‐phase proteinsEuropean Journal of Immunology, 1988
- EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCERThe Lancet, 1987